Search Results 161-170 of 13423 for Relaxin-2
Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...
... 2 hours, or HbA1c ≥ 6.5%), or IGT (plasma glucose ≥ 140 mg/dL and < 200 mg/dL on a 2-hour oGTT) (American Diabetes Association 2018);; Systolic ...
Patients with previously untreated low tumor burden indolent Non-Hodgkin's Lymphoma (NHL) will receive either rituximab or GA101 weekly for 4 weeks followed by ...
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of ...
... 2 dose (RP2D) for future study after treatment with SONALA-001 in combination ... Go to page 22 · Go to page 33 · Go to page 44 · Go to page 55 · NextNext Page.
... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.